Arranta Bio Announces Completion of Its Microbiome Process Development Laboratory Expansion and Commitment to Additional Early Clinical GMP Capacity (PR Newswire)

Arranta Bio Announces Completion of Its Microbiome Process Development Laboratory Expansion and Commitment to Additional Early Clinical GMP Capacity

Arranta Bio, the leading microbiome contract development and manufacturing organization (CDMO), announced the completion of its process development laboratory expansion project and a commitment to add additional early-clinical GMP capacity at its Center of Excellence for Microbiome Process Development and Early Clinical Supply.

Arranta has completed the expansion of purpose-built microbiome process development laboratories in a new dedicated building, which creates capacity for up to 45 process development scientists at its Gainesville, Florida site. Dr. Aaron Cowley, chief scientific officer at Arranta and the founder of Arranta’s legacy company said, “These laboratories will allow Arranta Bio to apply our 11 years of deep experience in developing processes for microbiome products to meet the needs of an increasing number of client programs. Our proprietary actALIVE™ program provides the fastest path to the clinic, from project start to IND submission in nine months, thus allowing clients to initiate proof of concept clinical trials on an accelerated timeline.”

Arranta Bio acquired UF Innovate | The Hub resident client Captozyme, now Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company developing a best-in-class enzyme therapeutic for secondary hyperoxaluria.

Learn more about Arranta Bio Announces Completion of Its Microbiome Process Development Laboratory Expansion and Commitment to Additional Early Clinical GMP Capacity.
X